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Cross-presentation of antigen by dendritic cells (DCs) to CD8+ T cells is a fundamen-
tally important mechanism in the defense against pathogens and tumors. Due to the
lack of an appropriate lineage marker, cross-presenting DCs in the mouse are provision-
ally classified as “Batf3-IRF-8-Id2-dependent DCs” or as “CD8+ DCs” in the spleen, and
as “CD103+CD11b− DCs” in the periphery. We have now generated a mAb to XCR1,
a chemokine receptor which is specifically expressed on CD8+ DCs and a subpopula-
tion of double negative DCs in the spleen. Using this antibody, we have determined that
only XCR1+CD8+ (around 80% of CD8+ DCs) and their probable precursors, XCR1+CD8−
DCs, efficiently take up cellular material and excel in antigen cross-presentation. In lymph
nodes (LNs) and peripheral tissues, XCR1+ DCs largely, but not fully, correspond to
CD103+CD11b− DCs. Most importantly, we demonstrate that XCR1+ DCs in the spleen,
LNs, and peripheral tissues are dependent on the growth factor Flt3 ligand and are selec-
tively absent in Batf3-deficient animals. These results provide evidence that expression
of XCR1 throughout the body defines the Batf3-dependent lineage of DCs with a spe-
cial capacity to cross-present antigen. XCR1 thus emerges as the first surface marker
characterizing a DC lineage in the mouse and potentially also in the human.
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INTRODUCTION
In the immune system, dendritic cells (DCs) are specialized on the
uptake and presentation of antigens to T cells. In the absence of
DC-specific markers, mouse “conventional DCs” (cDCs) are being
currently defined as lineage marker-negative hematopoietic cells
expressing high levels of MHC class II and the integrin CD11c. By a
number of criteria cDCs differ from “plasmacytoid DCs” (pDCs),
which only have a limited potential to take up and present antigen
(Villadangos and Young, 2008). In some antigen targeting studies,
splenic cDCs are subdivided into mutually exclusive CD205high
and DCIR2+ populations, the latter recognized by mAb 33D1
(Dudziak et al., 2007). More commonly, cDCs are classified into
CD4+ DCs (around 60% of DCs), CD8+ DCs (20%, encompass-
ing almost all CD205high DCs), and CD4−CD8− DCs (DN DCs,
20%; Vremec et al., 2000). These subdivisions allowed in the past
to recognize major differences between DC subsets, both in their
ontogeny and function. It was demonstrated that splenic CD8+
Abbreviations: cDC, conventional DC; DIG, digoxigenin; DN, double negative;
FMO, fluorescence minus one; pDC, plasmacytoid DC; TF, transcription factor.
DCs critically depend in their development on the growth factor
Flt3 ligand (Maraskovsky et al., 1996; McKenna et al., 2000) and
the transcription factor (TF) Batf3 (Hildner et al., 2008). Func-
tionally, CD8+ DCs were demonstrated to be particularly efficient
in the uptake of cells stressed by (intracellular) infection (Iyoda
et al., 2002; Schulz and Reis e Sousa, 2002; Schnorrer et al., 2006).
Moreover, CD8+ DCs have consistently been shown to excel in
antigen “cross-presentation,” in which antigen is not presented in
the context of MHC class II to CD4+ T cells, but instead shunted to
the MHC class I pathway and presented to CD8+ T cells (den Haan
et al., 2000; Pooley et al., 2001). Thus, splenic CD8+DCs were until
recently regarded as a coherent population of DCs closely cooper-
ating with CD8+ T cells in the surveillance of stressed/transformed
cells for “danger” (Shortman and Heath, 2010).
The equivalents of “classical CD8+ DCs” in the periphery of
the mouse immune system were not easily identifiable since CD8
is only expressed to a low degree on some DC subpopulations in
peripheral organs. Several lines of evidence indicated that in the
periphery CD103+CD11b− DCs largely correspond to the “classi-
cal CD8+ DCs,” but the use of CD103 and CD11b, even in combi-
nation with other markers, did not allow a consistent delineation
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of these DCs (Shortman and Heath, 2010; Hashimoto et al., 2011).
Recently, it became apparent that both the “classical splenic CD8+
DCs” and also their counterparts in the periphery are critically
dependent on the TFs Batf3, IRF-8 (also designated ICSBP), and
Id2 (Schiavoni et al., 2002; Aliberti et al., 2003; Hacker et al., 2003;
Hildner et al., 2008; Ginhoux et al., 2009; Edelson et al., 2010).
Since this TF-dependence appeared to be a consistent feature for
the cross-presenting DCs in the entire body, they were also termed
“Batf3-IRF-8-Id2-dependent DCs” (Hashimoto et al., 2011).
Using a reporter system, we have recently recognized that the
chemokine receptor XCR1 is exclusively expressed in splenic CD8+
DCs, in a subset of DN DCs, and in corresponding DCs in periph-
eral lymphoid tissues, but not in other cell types in the mouse
(Dorner et al., 2009). Similar results were independently obtained
by the group of Dalod (Crozat et al., 2010, 2011). Since antibod-
ies detecting the XCR1 protein were not available until now, all
observations on the specific expression of XCR1 in CD8+ DCs
were based on XCR1-reporter mice and extensive qPCR analyses
of purified cell populations.
We now have generated a mAb which specifically detects the
murine XCR1 receptor. This allowed us to follow up our ear-
lier observations that only around 80% of splenic CD8+ DCs
express XCR1 at mRNA level (Dorner et al., 2009). In our present
report we show that regarding XCR1 cell surface expression,
splenic CD8+ DCs are a heterogeneous population, with only
XCR1+CD8+DCs (but not XCR1−CD8+DCs) capable of antigen
cross-presentation. We further demonstrate that XCR1+DN DCs
resemble XCR1+CD8+ DCs in their phenotype and function, and
are apparently precursors of XCR1+CD8+ DCs. Our results show
that XCR1+ DCs and CD103+CD11b− DCs are largely congru-
ent populations in lymph nodes (LNs) and peripheral organs, but
additional XCR1+DCs can be found,which do not express CD103.
Most importantly, we provide evidence that the DC populations
expressing XCR1 in the spleen, LNs, and peripheral tissues are
selectively absent in Batf3-deficient animals. Thus, expression of
XCR1 uniformly characterizes a DC lineage known to excel in anti-
gen cross-presentation, recognized until now as “classical CD8+
DCs,” “CD103+CD11b− DCs,” or “Batf3-IRF-8-Id2-dependent
DCs.” The use of XCR1 as a “functional” marker will facilitate
the analysis of DC biology in vivo, also in the human, where XCR1
is expressed on a CD141+DC population homologous to“classical
CD8+ DCs” (Bachem et al., 2010; Crozat et al., 2010).
MATERIALS AND METHODS
MICE AND FLT3 LIGAND TREATMENT
Unless indicated otherwise, 8- to 10-week-old C57BL/6 female
mice were used for cell isolation and immunohistological analyses.
CX3CR1GFP (Jung et al., 2000), Lang-EGFP mice (Kissenpfen-
nig et al., 2005), B6.XCR1-LacZ (The Jackson Laboratories), and
Xcl1-deficient mice (Dorner et al., 2009) were on the C57BL/6
background. 129/Sv WT mice (129S2/SvPasCrl substrain) were
purchased from Charles River. Icsbp/Irf-8-deficient (Holtschke
et al., 1996) and Batf3-deficient mice (Hildner et al., 2008) were on
the 129/Sv background. OT-I TCR-transgenic mice were crossed
onto the B6.PL background to allow identification of CD8+ T cells
using the CD90.1 marker. For Flt3 ligand treatment, C57BL/6 mice
were injected with 1× 106 B16 cells secreting Flt3 ligand (Mach
et al., 2000) in 100 µl PBS s.c. All mice were bred under spe-
cific pathogen-free conditions in the animal facility of the Federal
Institute for Risk Assessment (Berlin, Germany). All animal exper-
iments were performed according to state guidelines and approved
by the local animal welfare committee.
ANTIBODIES
Hybridomas producing mAb recognizing CD4 (clone YTS 191.1),
CD8 (53-6.72), CD11b (5C6), CD11c (N418), CD16/32 (2.4G2),
CD19 (1D3), CD24 (M1/69.16.11.HL), CD45R/B220 (RA3-6B2),
DCIR2 (33D1), Ly6G/C (RB6-8C5), MHC class II (M5/114.15.2),
and NK1.1 (PK136) were obtained from ATCC, CD90.1 (OX-
7) from ECACC. MAb to CD103 (M290), CD172a (P84) were
from BD Biosciences, to CD69 (H1.2F3), CD317 (eBio927), and
PD-1 (J43) from eBioscience. Anti-mClec9A/DNGR-1 antibod-
ies 24/04-10B4 (Caminschi et al., 2008) and 1F6 (Sancho et al.,
2008) were used. Anti-CD3 (KT3) was generously provided by
H. Savelkoul, anti-CD25 (2E4) by E. Shevach, and anti-DEC205
(NLDC-145, CD205) by G. Kraal. Anti-ICOS (MIC-280) antibody
was generated as described before (Löhning et al., 2003).
GENERATION OF THE MONOCLONAL ANTI-MURINE XCR1 ANTIBODY
Homozygous B6.XCR1-lacZ mice were five times immunized i.p.
with 30× 106 CD11c-enriched cells from C57BL/6 WT mice in
combination with heat-inactivated B. pertussis (Chiron Behring).
One day after the last boost, splenocytes of the immunized mice
were fused with the myeloma cell line P3× 63Ag8.653 (ATCC)
according to standard methods. The resulting hybridomas were
screened for mAb against XCR1 by flow cytometry of DCs from
C57BL/6 WT mice enriched by density gradient centrifugation,
DCs from B6.XCR1-lacZ mice served as negative control. As sec-
ondary reagent, Cy5-AffiniPure Goat anti-Mouse IgG (Fcγ frag-
ment specific; Jackson ImmunoResearch) was used. Screening of
1,500 hybridomas yielded one specific mAb against XCR1, which
was designated MARX10 (IgG2b; determined by ELISA).
CELL ISOLATION
Splenocytes were obtained by mashing spleens through 70 µm cell
sieves into PBS, followed by erythrocyte lysis with ACK Buffer
(155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Where indi-
cated, DCs were enriched by cutting spleens into small pieces
followed by digestion with Collagenase D (500 µg/ml) and DNase
I (20 µg/ml, both Roche) for 20 min at 37˚C in RPMI 1640 con-
taining 2% FCS (low endotoxin, Biochrom); EDTA (10 mM) was
added for additional 5 min and cells were filtered through a 70-µm
nylon sieve (BD Falcon). Low density cells were further enriched by
centrifugation over a 1.073-g/ml density gradient (NycoPrep,Axis-
Shield), followed by magnetic cell sorting with CD11c microbeads
(Miltenyi Biotec). For isolation of gut DCs, the small intestine
was freed from fat and Peyer’s patches, opened longitudinally, and
stirred in PBS, 2% BSA, 1 mM EDTA, 1 mM DTT for 8 min at
37˚C. After additional stirring under the same conditions without
DTT, epithelial cells in solution were discarded, intestinal tissue
was minced, and stirred in 500 µg/ml Collagenase VIII (Sigma)
and 20 µg/ml DNAse I (Roche) for 45 min at 37˚C. Low density
cells were enriched by centrifugation over a 1.073-g/ml density
gradient. Skin-draining LNs (pooled inguinal and axillar LNs)
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and mesenteric LNs were mashed through sieves and subjected
to enzymatic digestion as described for splenic tissue. Lungs were
perfused with 10 ml PBS through the right ventricle of the heart
and separated from LNs. Lung tissue was cut into pieces, disso-
ciated with the gentleMACS (Miltenyi Biotec), and digested for
30 min with 20 µg/ml Liberase TM and DNase I (20 µg/ml, both
Roche) at 37˚C in RPMI 1640 containing 2% FCS (low endotoxin,
Biochrom); EDTA (10 mM) was added for additional 5 min to stop
Liberase activity. After further dissociation with the gentleMACS,
lung tissue was filtered through a 70-µm nylon sieve (BD Falcon)
and erythrocytes were lysed with ACK Buffer.
FLOW CYTOMETRY AND CELL SORTING
Antibodies were titrated for optimal signal-to-noise ratio. To block
unspecific binding to Fc-receptors, cells were pre-incubated with
100 µg/ml 2.4G2 mAb for flow cytometry and in addition with
50 µg/ml purified rat Ig (Nordic) for flow sorting. Standard stain-
ing with mAb was in PBS, 0.25% BSA, 0.1% NaN3 for 20 min on
ice, staining for Clec9A was in the same buffer for 20 min at 37˚C.
For exclusion of dead cells 4′,6-diamidino-2-phenylindole (DAPI)
was added 5 min before measurement. Data were acquired on a
LSR II flow cytometer (BD Biosciences),and analyzed using FlowJo
(Tree Star, Inc.). Doublets and autofluorescent cells were excluded
from the analysis. For lung stainings, CD45 was used to define
lymphocytes. In all organs, DCs were defined as CD11c+MHC
II+Lin− cells. The lineage cocktail contained mAbs directed to
CD3 and B220, a mAb to Ly6G/C was added for analyses of
splenocytes. DCs isolated from LN were considered as migratory
or resident based on their levels of MHC II expression. For flow
sorting of splenic DCs, CD11c+MHC class II+Lin− cells were
stained with the respective antibodies and sorted based on their
expression of CD8 and XCR1 on a FACSAriaII (BD Biosciences).
For cell uptake experiments, 300-19-∆OVA cells (Dorner et al.,
2009) were labeled with CFSE (10 µM, 12 min, 37˚C), washed,
and injected i.v. (10× 106 cells in 200 µl PBS).
HISTOLOGY
For standard histological analysis, cryostat sections (12 µm) of
spleens from C57BL/6 WT and B6.XCR1-lacZ (homozygous and
heterozygous) mice were fixed in acetone for 10 min at RT. Endoge-
nous peroxidase was inhibited with a blocking solution (PBS,
1 mM NaN3, 10 mM glucose, 1 U/mL glucose oxidase) for 1 h
at 37˚C. Unspecific binding sites were saturated with Casein
Solution (Vector Laboratories) supplemented with mAb 2.4G2
(100 µg/ml) and rat IgG (50 µg/mL) for 1 h at RT. Sections were
stained with DIG-coupled mAb MARX10 or FITC-conjugated
mAb KT3 or RA3-6B2, washed, and incubated with anti-DIG
Fab coupled to alkaline phosphatase or anti-fluorescein Fab
coupled to horseradish peroxidase (both Roche). The stainings
were developed using the Blue Alkaline Phosphatase Substrate
Kit and the ImmPACT DAB Peroxidase Substrate (both Vec-
tor Laboratories) sequentially. For confocal microscopy, sections
were stained with fluorophore-coupled antibodies and biotiny-
lated mAb MARX10, the XCR1-staining was amplified with
peroxidase-conjugated streptavidin (Jackson ImmunoResearch),
followed by fluorescence-labeled tyramide (TSA-Kit, Molecular
Probes). Nuclei were counterstained with DAPI (100 ng/ml) and
the sections analyzed on a LSM 780 with ZEN2010 imaging
software (Carl Zeiss).
CROSS-PRESENTATION ASSAY
For in vivo loading with antigen, C57BL/6 mice were injected i.v.
with either 2 mg OVA (Sigma-Aldrich) or 10× 106 300-19-∆OVA
cells (Dorner et al., 2009) in 200 µl PBS. Before injection, LPS
was removed from OVA using EndoTrap red (Hyglos) resulting in
<0.5 EU of endotoxin per milligram of protein as determined by
the LAL assay (Charles River). Twelve hours after injection with
soluble or cell-associated antigen, DC subsets were sorted to high
purity (>98.5%) as described in flow cytometry and cell sorting.
OT-I CD8+ T cells were enriched by depleting OT-I splenocytes
expressing CD4, CD11b, CD11c, B220, or NK1.1 using biotiny-
lated mAb and anti-biotin magnetobeads (Miltenyi Biotec); after
their resting state was confirmed using mAb directed to CD25,
CD69, PD-1, and ICOS, they were labeled with CFSE (5 µM,
10 min,37˚C). For cross-presentation assays,1× 105 CFSE-labeled
OT-I CD8+ T cells were co-cultured with titrated numbers of
DC subsets (1,000–30,000) in 200 µl RPMI medium contain-
ing 10% FCS, 50 µM 2-mercaptoethanol, and 100 µg/ml peni-
cillin/streptomycin in 96-well round-bottomed plates (Nunc) for
2.5 days. Thereafter, proliferation of OT-I CD8+ T cells was deter-
mined in the CFSE dilution assay after gating on CD90.1 cells. As
a positive control, sorted DC subsets from untreated mice were
loaded with 1 µM of the OVA peptide SIINFEKL in medium for
1 h at 37˚C, washed, and co-cultured with CFSE-labeled OT-I T
cells (1× 104 DCs, 1× 105 T cells) for 2.5 days.
STATISTICAL ANALYSIS
All statistical analyses were performed with Prism software
(GraphPad Software, Inc.). Differences between DC subsets were
analyzed by paired Student’s t -test, a p-value of <0.05 was
considered significant (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
RESULTS
GENERATION OF A MONOCLONAL ANTIBODY DIRECTED TO XCR1
Immunization of homozygous B6.XCR1-lacZ reporter mice with
C57BL/6 WT splenocytes enriched for CD11c+DCs yielded a mAb
recognizing murine XCR1. This antibody, designated MARX10,
specifically stained 20% (±4% SD, n= 22) of splenic cDCs in
C57BL/6 WT mice, but did not give a signal in homozygous
B6.XCR1-lacZ animals, which lack the XCR1 receptor (Figure 1A).
Similar stainings of cDCs were also obtained in BALB/c and 129/Sv
animals (not shown). pDCs did not express XCR1 (Figure 1B).
Negative for XCR1 were also T cells, B cells, macrophage subsets,
eosinophilic, and neutrophilic granulocytes, NK cells, NKT cells,
and γ/δ T cells (data not shown), as already reported at the mRNA
level (Dorner et al., 2009).
THE XCR1 RECEPTOR IS SELECTIVELY EXPRESSED ON CD8+ cDCs AND
A SUBSET OF DN cDCs
When subsets of cDCs were further analyzed based on their expres-
sion of CD4 and CD8, 83% (±6% SD, n= 22) of CD8+ DCs
stained positive for XCR1, while the remaining CD8+ DCs were
negative, as were the CD4+DCs (Figure 1C). Analysis of DN cDCs
consistently revealed a small but significant proportion (4± 1.8%
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FIGURE 1 | MAb MARX10 specifically recognizes XCR1 on subsets of
cDCs. Splenocytes from C57BL/6 (red lines) or homozygous B6.XCR1-lacZ
mice lacking the XCR1 receptor (gray lines) were stained with mAb
MARX10 and gated on (A) cDCs, (B) pDCs, or (C) the cDC subsets CD8+,
CD4+, and DN DCs. Shown are results representative of at least three
experiments.
SD, n= 19) of XCR1+ cells (Figure 1C). The flow cytometry data
thus fully reflected the results on the expression of XCR1 obtained
earlier using B6.XCR1-lacZ reporter mice (Dorner et al., 2009).
SPLENIC XCR1+ DCs ARE LOCALIZED IN THE T CELL ZONE, THE
MARGINAL ZONE, AND THE RED PULP
In order to determine the anatomical localization of XCR1+ DCs,
serial cryosections of spleens removed at steady state were stained
with mAb MARX10. Signals for XCR1 were obtained in T cell
zones, marginal zones, and the red pulp (Figures 2A–C), and were
thus concordant with our earlier data obtained with B6.XCR1-lacZ
reporter mice (Dorner et al., 2009). XCR1+ DCs broadly localized
to the same areas as the remaining CD11c+ cells (Figure 2C).
However, the highest density of XCR1-signals was observed in the
central parts of T cell zones, while signals for CD11c+XCR1− cells
were clustered at the border (Figure 2C). Of functional impor-
tance, the location of XCR1+ DCs in C57BL/6 WT animals was
identical to their location in Xcl−/− mice (Dorner et al., 2009
and data not shown). Moreover, the anatomical distribution of
the reporter signals in heterozygous B6.XCR1-lacZ mice, which
express XCR1, was identical to the signals obtained with homozy-
gous B6.XCR1-lacZ mice, which lack the XCR1 receptor (data not
shown). These results demonstrated that the positioning of splenic
XCR1+ DCs in the T cell zone, marginal zone, and the red pulp
at steady state is independent of XCR1 or its chemokine ligand
XCL1.
EXPRESSION OF XCR1 ON SPLENIC cDCs IS HIGHLY CORRELATED WITH
CD8, CD205, AND CLEC9A, BUT ANTI-CORRELATED WITH CD4, CD172a,
CD11b, CX3CR1, AND DCIR2
Since expression of XCR1 did not follow the subdivision of cDCs
based on CD4 and CD8, we compared its expression to a greater
number of other DC surface receptors. XCR1 was found to be
highly correlated with CD8, CD205, and Clec9A/DNGR-1, and
to a lesser degree with CD103, and CD207/langerin (Figure 3A).
An anti-correlation to XCR1 expression was observed with CD4
(as described above), and interestingly also with CD172a/SIRPα,
CD11b, CX3CR1/fractalkine receptor, and DCIR2 (also termed
33D1, Figure 3A).
XCR1+CD8+ AND XCR1+CD8− DCs ARE RELATED, AND DIFFERENT
FROM XCR1−CD8+ AND XCR1−CD8− DCs
To gain further understanding on the relationship of cells express-
ing XCR1, we compared splenic XCR1+CD8+ DCs (around
80% of “classical CD8+ DCs”) with XCR1+CD8− DCs (around
4% of “DN DCs”). Both DC subsets expressed CD205, CD86,
Clec9A, CD24, and both were lacking CD172a, CD4, and DCIR2
(Figure 3B). XCR1+CD8+ DCs exhibited lower levels of CD11b
and were low/negative for CX3CR1, but their expression of
CD103 and CD207 was clearly higher compared to their CD8-
negative counterparts (Figure 3B). An altogether different pat-
tern of surface receptors was observed on CD8+ DCs not
expressing XCR1. This population was low/negative for CD205,
CD103, and CD207, expressed some CD11b and Clec9A, was
positive for CD172a to a substantial degree, heterogeneous for
CD4, partly expressed DCIR2, and exhibited high levels of
CX3CR1. Finally, XCR1−CD8− DCs, the largest population of
DCs, were low/negative for CD24, CD103, CD207, and Clec9A,
expressed low levels of CD205, were largely CD4+, and were
positive for DCIR2, CD11b, CD172a, and CX3CR1 (with a sub-
population expressing high levels of this chemokine receptor,
Figure 3B). Based on this phenotypic analysis, XCR1+CD8+
DCs and XCR1+CD8− DCs appeared related, with XCR1+CD8−
partly differing in the expression of CD103, and CD207. The
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FIGURE 2 | Splenic XCR1+ DCs are localized in theT cell zone, marginal
zone, and the red pulp. Serial cryostat sections of C57BL/6 spleens were
double-stained for (A) XCR1 (blue) and B220 (brown), or (B) XCR1 (blue)
and CD3 (brown) using standard immunohistology, or (C) triple-stained for
XCR1 (green), CD3 (blue), and CD11c (red) with fluorescent mAb and
analyzed by confocal microscopy (Bars=100 µm). Shown are
representative images of two experiments.
phenotype of XCR1− cDCs was clearly different from XCR1+
DCs.
DEVELOPMENT OF SPLENIC XCR1+ DCs IS DEPENDENT ON FLT3
LIGAND, BATF3, AND IRF-8
In order to understand the ontogeny of splenic XCR1+ DCs,
we exposed C57BL/6 WT mice to Flt3 ligand, a growth factor
known to play a key role in the expansion of “classical CD8+
DCs” (Maraskovsky et al., 1996). Although XCR1− DCs expanded
to some degree (maximally sixfold), both XCR1+CD8+ and
XCR1+CD8− DCs expanded around 20-fold under the influence
of Flt3 ligand in vivo, so they together now constituted around 50%
of all cDCs, compared to 20% in untreated mice (Figures 4A,B).
This observation indicated a major influence of Flt3 ligand on
the ontogeny of all XCR1+ DCs, irrespective of their CD8 expres-
sion. Next, we examined the role of TFs known to control the
ontogeny of “classical CD8+ DCs” (Liu and Nussenzweig, 2010;
Hashimoto et al., 2011; Satpathy et al., 2011). In mice deficient for
the TF Batf3 (Hildner et al., 2008) or the TF IRF-8 (also designated
ICSBP, Holtschke et al., 1996), the size of the CD8+ DC popula-
tion was clearly reduced to around 5% or less (down from 15%
of 129Sv WT mice), and XCR1 could no longer be detected on
these remaining CD8+ DCs or on any other cDCs (Figure 4C).
These results indicated the requirement of Batf3 and IRF-8 in
the ontogeny of XCR1+ DCs, irrespective of their CD8 expres-
sion. Interestingly, the residual CD8+ DCs in the Batf3-deficient
animals partly expressed CD4 and were negative for CD205 and
CD103, and thus corresponded to the XCR1−CD8+ DC popula-
tion seen in 129Sv WT mice (Figure 4D) and C57BL/6 WT mice
(Figure 3B). The observation that in Batf3-deficient animals all
XCR1+ DCs were absent, while the CD8+ cDC population not
expressing XCR1 remained unaffected, suggested that XCR1+DCs
specifically depend in their ontogeny on Batf3.
UPTAKE OF LIFE CELLS IS HIGHLY CORRELATED WITH XCR1
EXPRESSION
In order to test the function of XCR1+ DCs in vivo, we injected
live, CFSE-labeled allogeneic 300-19 cells transfected with non-
secretable OVA (300-19-∆OVA) i.v., and determined their uptake
by the various splenic cDC subpopulations over time. At 2 h after
injection, more than 80% of the injected cells taken up by cDCs
were engulfed by XCR1+ DCs (Figure 5A). Within the DC popu-
lations, around 13% of all XCR1+CD8+DCs, 4% of XCR1+CD8−
DCs, 0.4% of XCR1−CD8+ DCs, and 0.2% of XCR1−CD8− DCs
have taken up 300-19 cells at 2 h, and this distribution remained
similar at later time points. On a per cell basis, the capacity of these
DC populations to take up the injected cells thus differed by relative
ratios of 64:22:2:1 (Figure 5B). This experiment revealed a good
correlation between high XCR1 expression (mainly XCR1+CD8+
DCs) and early uptake of cells. Later in the experiment, DCs
which have engulfed cellular material seemed to partly down-
regulate XCR1. However, expression of XCR1 remained clearly
detectable and that was also the case in different experiments
in which DCs were activated by injection of LPS i.v. (data not
shown).
ONLY XCR1+ DCs EFFICIENTLY CROSS-PRESENT SOLUBLE AND
CELL-ASSOCIATED ANTIGEN
In order to test the capacity of DC subsets for antigen cross-
presentation, 2 mg of soluble, endotoxin-free ovalbumin (OVA)
was injected i.v. into C57BL/6 WT animals. Fourteen hours later,
splenic CD11c+ DCs were sorted into four subsets, based on their
expression of XCR1 and CD8, and co-cultured with CFSE-labeled
OT-I transgenic CD8+ T cells at various ratios. The capacity of
the DC subsets for antigen cross-presentation was determined by
the degree of OT-I T cell proliferation (measured using the CFSE
dilution assay) after 60 h of co-culture. Loading of the DC sub-
sets with OVA peptide in vitro (without prior antigen loading
in vivo) was used as a positive control and gave identical OT-I T
cell proliferation with all DC subsets (Figure 6A). Within the DC
populations loaded with OVA in vivo, XCR1+CD8+ DCs cross-
presented soluble OVA with the same high efficiency as XCR1+
DCs lacking CD8 (Figure 6B). At the same time, all XCR1+ DCs
cross-presented soluble OVA clearly better than XCR1−CD8+
and XCR1−CD8− DCs (Figure 6B). When the experiment was
repeated with cell-associated antigen (300-19-∆OVA), XCR1+
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FIGURE 3 | Correlation of XCR1 expression with different DC markers.
Splenic cDCs of C57BL/6 WT, heterozygous CX3CR1GFP, or Lang-EGFP
(CD207) mice were enriched by digestion and density gradient centrifugation
and double-stained with mAb MARX10 and the indicated markers. For
Clec9A/DNGR-1 staining clone 24/04-10B4 is shown, similar staining was
obtained with clone 1F6. The gates were set on CD11c+MHCII+Lin− cells.
(A) Correlation and anti-correlation of XCR1 with the indicated surface
molecules on splenic cDCs. Shown are results representative of three
experiments. (B) Expression of the indicated surface markers on XCR1+CD8+
(red), XCR1+CD8− (orange), XCR1−CD8+ (green), and XCR1−CD8− (blue)
splenic cDCs. The background staining was determined with isotype or FMO
controls (gray). The data are representative of two or more experiments.
DCs excelled in antigen cross-presentation, again irrespective of
their CD8 expression, whereas XCR1−CD8+ and XCR1−CD8−
DCs essentially failed to cross-present OVA (Figure 6C). This dra-
matic difference most likely resulted from a combination of the
superior ability of XCR1+ DCs to take up live allogeneic cells
(see Figure 5), and their higher efficiency to cross-present antigen,
once the cell-associated antigen has been taken up (Figure 6B).
Altogether, these assays clearly demonstrated the higher capabil-
ity of XCR1+ DCs to cross-present antigen. Interestingly, in the
assays with soluble and cell-associated antigen, the smaller XCR1+
DC population lacking CD8, functionally behaved like the main
XCR1+CD8+ DC population.
XCR1+ DCs REPRESENT THE BATF3-DEPENDENT LINEAGE OF DCs IN
PERIPHERAL LYMPHOID TISSUE AND ORGANS
The similar phenotype of XCR1+CD8+ and XCR1+CD8− splenic
cDCs, their particularly strong expansion to Flt3 ligand, their spe-
cific absence in Batf3-deficient mice, and their superior capacity to
cross-present antigen indicated that XCR1 could be a marker for a
DC lineage with similar function in the entire immune system. In
order to test this hypothesis, we analyzed the CD103+CD11blow/−
DCs, the equivalents of the“classical CD8+DCs”in non-lymphoid
peripheral organs (Shortman and Heath, 2010; Hashimoto et al.,
2011) for their XCR1 expression and dependence on Batf3.
In the lamina propria of the gut, these CD103+CD11b− DCs
uniformly expressed XCR1, while the CD103+CD11b+ and
CD103−CD11b+ DCs were negative (Figure 7A, upper row). In
Batf3-deficient animals this XCR1+ population was totally absent
(Figure 7A, lower row). At the same time, the CD103−CD11b+DC
population increased in Batf3-deficient animals and may represent
Batf3-independent precursors. In the lung, the CD103+CD11b−
DCs again uniformly expressed XCR1, but here also approximately
half of the CD103+CD11b+ and half of the CD103−CD11b− DCs
were positive for XCR1, while the CD103−CD11b+ were uni-
formly negative (Figure 7B, upper row). Again, all XCR1+ lung
DC populations were absent in Batf3-deficient animals (Figure 7B,
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FIGURE 4 | Development of splenic XCR1+ DCs is dependent on the
growth factor Flt3 ligand and the transcription factors Batf3 and IRF-8.
(A,B) C57BL/6 mice were exposed to Flt3 ligand for 9 days in vivo.
Thereafter, spleens were removed, and the expression of CD8 and XCR1 on
splenic cDCs (CD11c+MHCII+Lin− cells) was compared to unexposed
controls. (A) Shown is one representative experiment out of four. (B) Fold
increase (based on frequencies of live) of the indicated cDC subsets in
relation to unexposed controls (mean±SEM; n=4; *p < 0.05; **p < 0.01).
(C) Splenocytes of 129/Sv WT controls, Batf3-deficient, or Irf-8 -deficient
mice were stained with mAbs directed to CD8 and XCR1; shown is the
expression of both markers on cDCs (CD11c+MHCII+Lin− cells). (D)
Splenocytes of 129/Sv WT controls (gray lines), or Batf3-deficient mice
(black lines) were stained for CD205, CD103, and CD4; shown are the
expression profiles after gating on XCR1−CD8+ cDCs. Data are
representative of two experiments.
lower row). Next, we examined LNs, where the CD11c+ DCs are
being classified into “resident” DCs with intermediate levels of
MHC class II, and “migratory” DCs with high levels of MHC class
II (Ohl et al., 2004). In mesenteric LNs, the CD8+ DC popula-
tion within the resident DCs uniformly expressed XCR1 and to
a large extent overlapped with CD103+ DCs (Figure 7C, upper
row). In Batf3-deficient animals, the XCR1+/CD8+ DC popula-
tion was fully absent, while the XCR1−CD103+ DCs remained
present (Figure 7C, lower row). Within the migratory mesen-
teric LN DCs, approximately half of the CD103+ DC population
expressed XCR1, and only this population was missing in Batf3-
deficient animals. Finally, we examined skin-draining DCs. Here,
almost all of CD8+ DCs and approximately half of CD103+ DCs
within the resident population were positive for XCR1 and expres-
sion of both CD8 and CD103 could no longer be detected in
Batf3-deficient animals. However, a XCR1+ DC population of
reduced size could still be detected, possibly representing precur-
sors which have not yet upregulated CD8 and CD103 (Figure 7D).
In the migratory population of skin-draining DCs, CD103 was
highly correlated with XCR1 in WT mice, and the entire popula-
tion was missing in Batf3-deficient animals (Figure 7D). Of note,
in none of the examined tissues and LNs CD103−CD11b+ cells
expressed XCR1 (not shown). When we examined IRF-8-deficient
mice, XCR1+ DCs were absent in all described organs and LNs
(including skin-draining LNs); at the same time, the lymphoid
system showed additional signs of heavy disruption (not shown).
Collectively, these data revealed that XCR1+ DCs in peripheral
lymphoid organs and tissues, like their counterparts in the spleen,
are in their development dependent on the TFs Batf3 and IRF-
8. Even more interestingly, the results indicated that expression
of XCR1 characterizes the Batf3-dependent lineage of DCs not
only in the spleen, but also in peripheral lymphoid tissues and
organs.
DISCUSSION
Since the identification of DCs in 1973 (Steinman and Cohn,
1973), many attempts have been undertaken to classify this het-
erogeneous cell type into subsets in order to better understand
the contribution of individual DC subpopulations to antigen pro-
cessing and presentation (Shortman and Heath, 2010; Steinman,
2012). Such a classification can be based on different criteria.
Expression of surface proteins and secreted molecules on DCs can
be considered, which together define the communication interface
with other cells of the immune system. This approach is limited by
the fact that many of these communication molecules are subject
to up- or downregulation in the course of DC differentiation and
also in the interaction with other cells. Gene expression profiling
can more broadly define the functional status of DC subpopula-
tions, but principally similar limitations apply. At the same time,
gene expression profiling by itself, without meaningful preselec-
tion of cell populations, cannot identify subsets of cells within
a given population. A powerful approach for the classification
of DCs is the understanding of their ontogeny and differentia-
tion (Liu and Nussenzweig, 2010; Hashimoto et al., 2011; Satpathy
et al., 2011). Finally, and most importantly, classification of DCs
has to be based on their particular capacity to take up, process, and
present antigen.
Only very few surface molecules are in their expression
restricted to cDCs,making the identification of DCs in flow cytom-
etry or their localization in tissues inherently complex. Therefore,
our previous observation that the chemokine receptor XCR1 was
selectively expressed in cDCs, but not elsewhere in the body, was
intriguing (Dorner et al., 2009). These observations were based on
a LacZ XCR1-reporter mouse and qPCR analyses, but could not
provide information on XCR1 surface expression. In our current
work, we have generated a mAb specific for murine XCR1 allowing
us to precisely determine the surface expression of the XCR1 recep-
tor in the body. Our flow cytometry data demonstrated that XCR1
is present on around 80% of “classical CD8+ DCs” and on 4%
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FIGURE 5 | XCR1+ DCs specifically take up cell-associated antigen.
C57BL/6 mice were injected with 10×106 CFSE-labeled allogeneic
300-19-∆OVA cells i.v., and cDCs (CD11c+MHCII+Lin− cells) were analyzed for
CFSE signals 2, 4, 12, and 24 h later. (A) The XCR1+CD8+ (red), XCR1+CD8−
(only here black!), XCR1−CD8+ (green), and XCR1−CD8− (blue)
subpopulations are color-coded. Note that XCR+CD8− DCs express lower
levels of XCR1 compared to XCR1+CD8+ DCs. Shown is one representative
experiment out of three. (B) Relative ratio of cell uptake capacity, calculated
for each animal by setting the frequency of XCR1−CD8− DCs exhibiting a
CFSE-signal to 1 and calculating the fold higher uptake for the other DC
subsets accordingly (mean±SEM of two independent experiments with
three animals each; *p < 0.05; **p < 0.01; ***p < 0.001).
FIGURE 6 | XCR1+ DCs excel in cross-presentation of soluble and
cell-associated antigen. Spleens were digested, CD11c+ cells enriched by
density gradient centrifugation and positive magnetic separation, and the
XCR1+CD8+, XCR1+CD8−, XCR1−CD8+, and XCR1−CD8− DC subsets
flow-sorted to purity (≥98.5%). (A) The respective DC subsets were loaded
with SIINFEKL peptide in vitro and co-cultured with CFSE-labeled OT-I T cells.
Shown is the CFSE dilution profile of OT-I T cells (CD90.1+CD8+) after 60 h of
co-culture with SIINFEKL-loaded DCs (black histograms) or non-loaded DC
controls (gray histograms). (B,C) C57BL/6 mice were injected with either
(B) 2 mg soluble OVA or (C) 10×106 allogeneic cells expressing
non-secretable OVA (300-19-∆OVA cell line). Spleens were removed 14 h later
and DCs were sorted to purity (≥98.5%) based on their expression of XCR1
and CD8, as above. Indicated numbers of the DC subsets were then
co-cultured with 1×105 CFSE-labeled OT-I T cells before analysis of the
CSFE-dilution profile. Shown is the percentage of OT-I T cells proliferating after
60 h of co-culture with XCR1+CD8+ (red), XCR1+CD8− (orange), XCR1−CD8+
(green), and XCR1−CD8− DCs (blue). The error bars represent SEM. Shown
are representative results of at least three experiments.
of “DN” DCs in the spleen and on DC subsets in peripheral LNs
and organs, but not on other cell types. Together with an extensive
histological examination of tissues (data not shown), these results
confirmed the DC-specific expression of XCR1.
The obtained surface expression profile of XCR1+ DCs could
not be fully accommodated into the “classical” subdivision of
splenic cDCs into CD8+ DCs, CD4+ DCs, and DN DCs (Vremec
et al., 2000), raising questions about the relationship and func-
tional relevance of DCs expressing XCR1. In our present work, we
observed that DN splenic DCs expressing XCR1 (“XCR1+CD8−
DCs”) and XCR1+CD8+ DCs shared a similar phenotype,
which differed from the remaining splenic DCs. Regarding their
ontogeny, both XCR1+ DC populations were selectively expanded
by the growth factor Flt3 ligand, which earlier has been shown
to specifically expand “classical CD8+ DCs” (Maraskovsky et al.,
1996). Both XCR1+CD8+ and XCR1+CD8− DCs were missing
in mice deficient for the TF IRF-8 and also in mice deficient for
the TF Batf3, a model system in which 70–90% of CD8+ DCs
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FIGURE 7 | Batf3-deficient mice lack XCR1+ DCs in peripheral
non-lymphoid and lymphoid tissues. (A) Expression of XCR1 (black
histograms) on gut lamina propria cDCs (CD11c+MHC II+Lin−) subdivided
into CD103+CD11b−, CD103+CD11b+, and CD103−CD11b+ subsets in
129/Sv WT controls (upper row) and Batf3-deficient mice (lower row); the
background signal (shaded histograms) was determined using
homozygous B6.XCR1-lacZ mice. (B) Expression of XCR1 on lung cDCs
(CD45+CD11c+MHC II+Lin− autofluorescence negative) subdivided into
CD103+CD11b−, CD103+CD11b+, CD103−CD11b+, and CD103−CD11b−
subsets in 129/Sv WT controls (upper row) and Batf3-deficient mice (lower
row). (C, D) Presence of XCR1+ DCs in resident (CD11c+MHCintLin−) and
migratory (CD11c+MHCIIhighLin−) cDC populations of (C) mesenteric or (D)
skin-draining lymph nodes in 129/Sv WT controls (upper row) and
Batf3-deficient mice (lower row). The results were obtained in two
independent experiments. The expression of XCR1 on the various DC
subpopulations in C57BL/6 mice was similar.
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are absent and in which antigen cross-presentation is severely
impaired (Hildner et al., 2008; Bar-On et al., 2010). In terms of
function, only the two splenic XCR1+ DC subsets were capable
of phagocytosing allogeneic cells injected into the circulation, as
has been originally demonstrated for “classical CD8+ DCs” (Iyoda
et al., 2002). Finally, and most importantly, only XCR1+ DCs
(irrespective of their CD8 expression) were efficient in the cross-
presentation of soluble or cell-associated antigen,while CD8+DCs
not expressing XCR1 fully failed.
In recent years, evidence accumulated that there is no strict
correlation between CD8 expression and cross-presentation, since
splenic CD8+ cDCs were recognized as heterogeneous and also
some CD8− DCs were shown to have cross-presenting capacity.
Lin et al. (2008) noticed that injection of cytochrome c depleted
a proportion of CD8+ DCs, most strongly affecting the abil-
ity to cross-present cell-associated antigen in vivo. Qiu et al.
(2009) determined that uptake of allogeneic apoptotic cells, as
well as cross-presentation of soluble and cell-associated antigen,
is strongly associated with CD8+ DCs co-expressing CD103 and
CD207, but not with CD8+ DCs lacking these two molecules. Far-
rand et al. (2009) also found that only CD207+CD8+ DCs, but not
CD207−CD8+ DCs could cross-present soluble antigen injected
in vivo. Bar-On et al. (2010) segregated CD8+ DCs based on their
expression of CX3CR1, the fractalkine receptor. CX3CR1+CD8+
DCs, in contrast to CX3CR1−CD8+ DCs, were not expanded by
Flt3 ligand, were not affected in Batf3-deficient mice, were spared
from the effect of injected cytochrome c, and did not secrete IL-
12p70 upon stimulation with CpG. The authors did not perform
any antigen (cross) presentation experiments, but concluded on
the basis of their data that CX3CR1+CD8+ DCs lack all hallmark
features of “classical CD8+ DCs.”
When comparing our phenotypic and functional data on
splenic DCs with the results of the groups outlined above, it
is apparent that the XCR1−CD8+ DCs, still present in Batf3-
deficient animals and incapable of antigen cross-presentation,
correspond to the splenic CD8+ DC population more exten-
sively described by Bar-On et al. (2010). Further comparison
clearly shows that the XCR1+CD8+ DC population corresponds
to CD8+DCs expressing CD205,Clec9A,CD103,CD207,but lack-
ing CX3CR1. Thus, within the CD8+ DCs, only the XCR1+CD8+
DCs truly represent the “classical CD8+ DCs” described to phago-
cytose apoptotic cells (Iyoda et al., 2002), to cross-present antigen
(den Haan et al., 2000; Pooley et al., 2001), and to secrete IL-12p70
(Hochrein et al., 2001).
Regarding the XCR1+CD8− DCs (XCR1+ “DN” DCs), Vremec
et al. (2007) described DN DCs characterized as highly positive for
CD24 but lacking CD172a, and having some cross-presentation
capability in vitro and in vivo. Bedoui et al. (2009) characterized a
CD8− cDC population expressing CD24 but lacking CD11b and
CD172a, which was substantially expanded by Flt3 ligand in vivo
and showed cross-presentation activity after loading with antigen
in vitro. This population, when adoptively transferred into syn-
geneic hosts, acquired the CD8 surface marker over the course of
several days, allowing the authors to conclude that these DCs are
precursors of CD8+DCs. Considering these phenotypic and func-
tional data, it is quite apparent that the DC population described
by both groups are the XCR1+CD8− DCs.
In the spleen thus only CD8+ DCs expressing XCR1 on the
surface correspond to the “classical CD8+ DCs” known to cross-
present antigen. XCR1+CD8− DCs, a subpopulation of “classical
DN DCs,” are apparently precursors of XCR1+CD8+ DCs, which
have not yet acquired the final surface density of XCR1 and have
not yet upregulated CD103 and CD207. These XCR1+CD8− DCs
are not yet fully efficient in the uptake of cell-associated antigen,
but are already endowed with the capacity to cross-present solu-
ble antigen in vivo. The cross-presentation capacity in the spleen
is thus provided collectively by XCR1+CD8+ and XCR1+CD8−
DCs.
In peripheral lymphoid organs and tissues, identification of
“CD8+DC equivalents”remained difficult. CD8, although present
on resident DCs in peripheral LNs, is not clearly expressed on
migratory DCs in LNs or on DCs in tissues, and thus could not
be universally used as a marker. Instead, a variety of other sur-
face molecules, among them CD103, CD11b, CD172a, F4/80, and
CX3CR1 were used in attempts to demarcate the“CD8+DC equiv-
alents” in tissues other than spleen. These approaches revealed that
CD103+CD11b− DCs share a specific gene expression pattern
with splenic “classical CD8+ DCs” (Edwards et al., 2003; Edelson
et al., 2010; Crozat et al., 2011), and are dependent on the TFs
Batf3, IRF-8, and Id2 (Schiavoni et al., 2002; Aliberti et al., 2003;
Hildner et al., 2008; Ginhoux et al., 2009; Edelson et al., 2010).
As a result, “CD103+CD11b− DCs,” or alternatively “Batf3-IRF-
8-Id2-dependent DCs” are currently being regarded as peripheral
equivalents of “classical CD8+ DCs” (Shortman and Heath, 2010;
Hashimoto et al., 2011). Based on a phenotypical analysis of XCR1-
reporter mice and gene expression studies, Crozat et al. (2011)
recently proposed that CD8α+ and CD103+ DCs belong to a
common DC subset characterized by XCR1 expression.
In our work on peripheral DCs, expression of XCR1 coincided
with the presence of CD8 on LN resident DCs, and was highly cor-
related with CD103+CD11b− DCs in all tissues. However, in some
tissues also about half of CD103+CD11b+ and CD103−CD11b−
DCs expressed XCR1 on the surface. Thus, XCR1+ DCs in the
periphery could not be easily accommodated into the current
definition of “CD8+ DC equivalents” based on the expression of
CD103 and CD11b only. Interestingly, however, peripheral XCR1+
DCs were uniformly missing in Batf3-deficient mice (with the
partial exception of skin-draining DCs), while substantial popu-
lations of CD103+ DCs remained present. Altogether, our results
revealed an almost perfect correlation between Batf3-dependency
and XCR1 expression for DCs in various lymphoid and non-
lymphoid organs in the periphery. In IRF-8-deficient mice, XCR1+
DCs were missing, but also additional immune populations were
absent (data not shown).
The consistent and apparently selective absence of XCR1+DCs,
both in the spleen and the periphery of Batf3-deficient animals,
strongly indicates that expression of XCR1 stringently character-
izes the Baf3-dependent lineage of DCs in the immune system.
None of the current surface molecules used to define “CD8-type”
cross-presenting DCs shows this specificity. Both CD8 and the
integrin CD103 are expressed on Batf3-independent DCs which
are incapable of antigen cross-presentation, and in addition on
other cell types in the immune system (Heath and Carbone,
2009; Hashimoto et al., 2011). CD205, also functionally linked
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to cross-presentation in splenic cDCs (Jiang et al., 1995; Dudziak
et al., 2007), is also expressed on B cells, epithelial cells, and stro-
mal cells (Inaba et al., 1995; Witmer-Pack et al., 1995). Clec9A is
correlated with XCR1 in the spleen, but is also found on splenic
XCR1−CD8+ DCs (this work and Caminschi et al., 2012), on
pDCs, and a subset of B cells (Caminschi et al., 2008; Sancho et al.,
2008). Thus, expression of XCR1 uniquely defines a lineage of DCs
with apparently similar function throughout the immune system.
This correlation of XCR1 expression with DC function will facil-
itate future analysis of DC biology in the mouse and potentially
also in the human.
Based on our work in the mouse and on the subsequent recog-
nition that peripheral blood XCR1+DCs are the human homologs
of murine “classical CD8+ DCs,” we (Dorner et al., 2009; Bachem
et al., 2010) and others (Crozat et al., 2010) have proposed that
targeting of antigen to XCR1+ DCs in vivo may be a valid option
to induce CD8+ T cell cytotoxic immunity against pathogens
or tumors in man. With the recognition that XCR1 is selec-
tively expressed on DCs specialized on antigen cross-presentation
in the entire immune system, this notion becomes even more
attractive.
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During the submission process of this manuscript we became
aware of the work of L.F. Poulin et al. (Blood online prepublica-
tion, doi: 10.1182/blood-2012-01-406967), in which the authors
describe DNGR-1/Clec9A as a specific marker for mouse and
human Batf3-dependent DCs. In our own work, expression of
Clec9A on splenic cDCs was highly congruent with XCR1. A con-
gruence of Clec9A and XCR1 expression may also be true in
peripheral organs, but due to the low signal intensity of Clec9a
staining in peripheral tissues we could not assess any correlation
there. However, there is a clear difference between these two surface
receptors. Clec9A is also expressed on murine pDCs and on a small
subset of B cells (Caminschi et al., 2008; Sancho et al., 2008), popu-
lations which are independent of Batf3 in their ontogeny (Hildner
et al., 2008), while XCR1 is exclusively expressed on cDCs. We
thus conclude that only expression of XCR1 closely reflects the
Batf3-dependent lineage of murine cDCs.
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